Ddavp

Do not take it if

Quoted from the official label, section “Contraindications”.

How to take it

These directions are for this exact strength and form. Another one is different.

• Central Diabetes Insipidus The dosage of DDAVP Tablets must be determined for each individual patient and adjusted according to the diurnal pattern of response.
• Response should be estimated by two parameters:
• adequate duration of sleep and adequate, not excessive, water turnover.
• Patients previously on intranasal DDAVP therapy should begin tablet therapy twelve hours after the last intranasal dose.
• During the initial dose titration period, patients should be observed closely and appropriate safety parameters measured to assure adequate response.
• Patients should be monitored at regular intervals during the course of DDAVP Tablet therapy to assure adequate antidiuretic response.
• Modifications in dosage regimen should be implemented as necessary to assure adequate water turnover.
• Fluid restriction should be observed.
• (See WARNINGS , PRECAUTIONS, Pediatric Use and Geriatric Use .)
• Adults and Children It is recommended that patients be started on doses of 0.05 mg (½ of the 0.1 mg tablet) two times a day and individually adjusted to their optimum therapeutic dose.
• Most patients in clinical trials found that the optimal dosage range is 0.1 mg to 0.8 mg daily, administered in divided doses.
• Each dose should be separately adjusted for an adequate diurnal rhythm of water turnover.
• Total daily dosage should be increased or decreased in the range of 0.1 mg to 1.2 mg divided into two or three daily doses as needed to obtain adequate antidiuresis.
• See Pediatric Use subsection for special considerations when administering desmopressin acetate to pediatric diabetes insipidus patients.
• Geriatric Use This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.
• Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
• (See CLINICAL PHARMACOLOGY, Human Pharmacokinetics , CONTRAINDICATIONS , and PRECAUTIONS, Geriatric Use .) Primary Nocturnal Enuresis The dosage of DDAVP Tablets must be determined for each individual patient and adjusted according to response.
• Patients previously on intranasal DDAVP therapy can begin tablet therapy the night following (24 hours after) the last intranasal dose.
• The recommended initial dose for patients age 6 years and older is 0.2 mg at bedtime.
• The dose may be titrated up to 0.6 mg to achieve the desired response.
• Fluid restriction should be observed, and fluid intake should be limited to a minimum from 1 hour before desmopressin acetate administration, until the next morning, or at least 8 hours after administration.
• (See WARNINGS , PRECAUTIONS, Pediatric Use and Geriatric Use .)

Quoted from the official label, section “Dosage & Administration”.

Other warnings

Quoted from the official label, section “Warnings”.

Pregnancy and breastfeeding

Quoted from the official label, section “OTC — Pregnancy or Breast Feeding”.

Other medicines

Quoted from the official label, section “Drug Interactions”.

If you take too much

In an emergency, call your local emergency number or a poison control centre.

Quoted from the official label, section “Overdosage”.

Use in children

• Central Diabetes Insipidus DDAVP Tablets (desmopressin acetate) have been used safely in pediatric patients, age 4 years and older, with diabetes insipidus for periods up to 44 months.
• In younger pediatric patients the dose must be individually adjusted in order to prevent an excessive decrease in plasma osmolality leading to hyponatremia and possible convulsions; dosing should start at 0.05 mg (½ of the 0.1 mg tablet).
• Use of DDAVP Tablets in pediatric patients requires careful fluid intake restrictions to prevent possible hyponatremia and water intoxication.
• Fluid restriction should be discussed with the patient and/or guardian.
• (See WARNINGS .) Primary Nocturnal Enuresis DDAVP Tablets have been safely used in pediatric patients age 6 years and older with primary nocturnal enuresis for up to 6 months.
• Some patients respond to a dose of 0.2 mg; however, increasing responses are seen at doses of 0.4 mg and 0.6 mg.
• No increase in the frequency or severity of adverse reactions or decrease in efficacy was seen with an increased dose or duration.
• The dose should be individually adjusted to achieve the best results.
• Treatment with desmopressin for primary nocturnal enuresis should be interrupted during acute intercurrent illness characterized by fluid and/or electrolyte imbalance (e.g., systemic infections, fever, recurrent vomiting or diarrhea) or under conditions of extremely hot weather, vigorous exercise or other conditions associated with increased water intake.

Quoted from the official label, section “Pediatric Use”.

Use in older people

• Clinical studies of DDAVP Tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
• Other reported clinical experience has not identified differences in responses between the elderly and younger patients.
• In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
• This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.
• Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
• DDAVP is contraindicated in patients with moderate to severe renal impairment (defined as a creatinine clearance below 50 mL/min).
• (See CLINICAL PHARMACOLOGY, Human Pharmacokinetics and CONTRAINDICATIONS .) Use of DDAVP Tablets in geriatric patients requires careful fluid intake restrictions to prevent possible hyponatremia and water intoxication.
• Fluid restriction should be discussed with the patient.
• (See WARNINGS .)

Quoted from the official label, section “Geriatric Use”.

Side effects

• Infrequently, large doses of the intranasal formulations of DDAVP and DDAVP Injection have produced transient headache, nausea, flushing and mild abdominal cramps.
• These symptoms have disappeared with reduction in dosage.
• Central Diabetes Insipidus In long-term clinical studies in which patients with diabetes insipidus were followed for periods up to 44 months of DDAVP Tablet therapy, transient increases in AST (SGOT) no higher than 1.5 times the upper limit of normal were occasionally observed.
• Elevated AST (SGOT) returned to the normal range despite continued use of DDAVP Tablets .
• Primary Nocturnal Enuresis The only adverse event occurring in ≥3% of patients in controlled clinical trials with DDAVP Tablets that was probably, possibly, or remotely related to study drug was headache (4% DDAVP, 3% placebo).
• Other The following adverse events have been reported; however their relationship to DDAVP has not been established:
• abnormal thinking, diarrhea, and edema-weight gain.
• See WARNINGS for the possibility of water intoxication and hyponatremia.
• Post Marketing:
• There have been rare reports of hyponatremic convulsions associated with concomitant use with the following medications:
• oxybutinin and imipramine.

Quoted from the official label, section “Adverse Reactions”.

What it looks like and how it is packed

• Strength Size NDC Code Color Markings 0.1 mg Bottle of 100 55566-2600-0 White 0.2 mg Bottle of 100 55566-2700-0 White Figure Figure
• Store at Controlled Room Temperature 20 to 25°C (68 to 77°F) [see USP].
• Avoid exposure to excessive heat or light.
• This product should be dispensed in a container with a child-resistant cap.
• Keep out of the reach of children.

Quoted from the official label, section “How Supplied”.

How to store it

• Store at Controlled Room Temperature 20 to 25°C (68 to 77°F) [see USP].
• Avoid exposure to excessive heat or light. This product should be dispensed in a container with a child-resistant cap.
• Keep out of the reach of children.

Quoted from the official label, section “Storage and Handling”.

What is in it

• DDAVP® Tablets (desmopressin acetate) are a synthetic analogue of the natural pituitary hormone 8-arginine vasopressin (ADH), an antidiuretic hormone affecting renal water conservation.
• It is chemically defined as follows: Mol.
• Wt.
• 1183.34 Empirical Formula:
• C 46 H 64 N 14 O 12 S 2 ∙C 2 H 4 O 2 ∙3H 2 O 1-(3-mercaptopropionic acid)-8-D-arginine vasopressin monoacetate (salt) trihydrate.
• DDAVP Tablets contain either 0.1 or 0.2 mg desmopressin acetate.
• Inactive ingredients include: lactose, potato starch, magnesium stearate and povidone.
• Chemical Structure

Quoted from the official label, section “Description”.

Ingredients people check for

Lactose, gluten, dyes, sugars and other ingredients that matter with an allergy, intolerance or diet — as this product’s FDA label lists them.

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

Details

Source: NDC Directory · 2026-09-13 · not reviewed by a clinician

Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).

Report wrong or outdated information on this page

Other strengths and forms

3 products are sold under this name. Grouped by form; a number on a strength means several companies make it.

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.

See every product with Desmopressin Acetate